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Despite the importance of telomere maintenance in
cancer cell survival via the elongation of telomeres
by telomerase reverse transcriptase (TERT) or alter-
native lengthening of telomeres (ALT), it had not
been tested directly whether telomere maintenance
is dispensable for human tumorigenesis. We engi-
neered human tumor cells containing loxP-flanked
hTERT to enable extensive telomere elongation prior
to complete hTERT excision. Despite unabated telo-
mere erosion, hTERT-excised cells formed tumors in
mice and proliferated in vitro for up to 1 year. Telome-
rase reactivation or ALT was not observed, and the
eventual loss of telomeric signal coincided with
loss of tumorigenic potential and cell viability. Crisis
was averted via the reintroduction of active but not
inactive hTERT. Thus, telomere maintenance is
dispensable for human tumorigenesiswhen telomere
reserves are long. Yet, despite telomere instability
and the presence of oncogenic RAS, human tumors
remain susceptible to crisis induced by critically
short telomeres.
INTRODUCTION
The limited in vitro life span of normal human cells, referred to as
the Hayflick limit, cellular senescence, or mortality stage 1 (M1),
was first described in 1961 (Hayflick, 1973). The temporal onset
of senescence is correlated tightly to telomere length (Allsopp
et al., 1992; Harley et al., 1990), and is bypassed by expression
of the telomerase reverse transcriptase hTERT (Bodnar et al.,
1998; Vaziri and Benchimol, 1998). Transformation via factorssuch as SV40 T antigen lead to life span extension beyond M1;
however, cells acquire genetic instability and eventually undergo
apoptosis, referred to as M2 or crisis (Wright et al., 1989).
Further, the discovery that tumor cells possessed shorter telo-
meres compared with normal tissues suggested that telomere
maintenance was required to avert crisis during tumorigenesis
(de Lange et al., 1990; Hastie et al., 1990). This hypothesis was
borne out in SV40-transformed human cells, in which rare clones
that acquired telomerase activity survived the genetic instability
and cell death that accompany crisis (Counter et al., 1992). In
fact, enforced expression of TERT in combination with onco-
genic RAS and the SV40 early region (ER) elicits tumorigenic
conversion of fibroblast, kidney epithelial, and mammary epithe-
lial cells (Elenbaas et al., 2001; Hahn et al., 1999a, 2002). Thus,
the acquisition of telomerase activity appears essential for
immortality in many normal and cancer cell types.
While mice have proven a useful model system in which to
study cancer, the response to a critically short telomere differs
markedly between mice and humans (for review, see Smogor-
zewska and de Lange, 2002). Another critical difference between
mice and humans is that many human tumor cell types possess
a subset of telomeres that are already critically short (Capper
et al., 2007; Xu and Blackburn, 2007), whereas laboratory murine
strains typically possess much longer average telomere lengths
(Hemann and Greider, 2000). For example, inhibition of telome-
rase reverse transcriptase (TERT) in human tumor lines induces
cell death almost immediately, confounding the ability to distin-
guish the role of TERT in cell viability independent of telomere
maintenance (Hahn et al., 1999b; Zhang et al., 1999). Thus, an
important unresolved question is whether TERT, or indeed any
mechanism of telomere maintenance, is essential for human
tumorigenesis.
To address this question, we engineered a human tumor
line in which telomere length and hTERT expression could
be controlled genetically and temporally. We employed theCell Reports 1, 91–98, February 23, 2012 ª2012 The Authors 91
Figure 1. An hTERT-Excisable Tumorigenic Cell Line
(A) Western analysis of whole-cell lysates (50 mg) from HA5, HT (HA5 + TERT),
and HTR (HT + RAS) cells at indicated population-doubling level (PDL).
(B) RT-PCR analysis of hTERT, hph, and GAPDH at indicated PDL.
(C) Analysis of telomerase activity of cell lysates (200, 100, 50 ng) at indicated
PDL. LB, negative buffer control; CTL, HeLa cell lysate-positive control; IC,
internal control PCR product.
(D) Replicative life span of HA5, HT, and HTR cells. HT or HTR cells were
immortal.
(E) Anchorage-independent colony growth at indicated PDL (n = 3). 293T
cells were a positive control for colony formation. Statistical significance
between HA5 (no colonies formed) and HT or HTR cell lines as indicated
(n = 3, ***p < 0.001; ns, p > 0.05, power(1-b err prob) > 0.99, aactual = 0.05, two
tailed).
(F) TRF analysis of average telomere length at increasing PDL. 293T cells were
included as a control. Weighted mean telomere lengths (kbp) are indicated
below each lane.
92 Cell Reports 1, 91–98, February 23, 2012 ª2012 The AuthorsCre-loxP system, which enables stringent and reversible control
of hTERT in primary human cells to generate human tumor cells
with long telomeres fromwhich hTERT could be excised (Cascio,
2001; Jaiswal et al., 2007; Steinert et al., 2000; Ungrin and
Harrington, 2006). The results demonstrated unequivocally that
TERT is dispensable for human tumorigenesis and cell viability
when telomeres are long. However, despite the continuous
presence ofRAS andSV40, induction of endogenous telomerase
or other telomere maintenance mechanisms (e.g., ALT) was
not observed, and the cells eventually succumbed to telomere-
induced crisis.
RESULTS
Establishment of hTERT-Excisable Human Tumor Cells
The human TERT cDNA (Harrington et al., 1997) and an
Escherichia coli phosphotransferase gene encoding resistance
to hygromycin B (hph) (Gritz and Davies, 1983) were flanked by
loxP sites and introduced into human HA5 embryonic kidney
cells (HA5) containing the SV40 early region (ER) (Stewart and
Bacchetti, 1991; Figure 1). Upon hTERT introduction, HT
(HA5 + hTERT) cells became telomerase-positive and immortal
but could not support anchorage-independent growth in 0.6%
w/v agar. However, after infection with a retrovirus encoding
HRASG12V (HT + RAS = HTR) (Hahn et al., 1999a), HTR cells
formed colonies in 0.6% w/v agar and gave rise to tumors in
immunocompromised mice when injected subcutaneously or
beneath the kidney capsule epithelium (Figures 1 and 2H). In
this tumor cell model, we chose to use an SV40-transformed
cell line (HA5) that cannot escape crisis spontaneously (Counter
et al., 1992), and hTERT was introduced as the second (rather
than first) step in the tumorigenic conversion process (Elenbaas
et al., 2001; Hahn et al., 1999a, 2002). Thus, immortalization is
not an obligate first step for human tumorigenesis.
TERT-Excised Tumor Cells with Short Telomeres
Capable of Transient Tumor Formation
Aftera short periodofpropagation inculture (population-doubling
level [PDL] 12,mean TRF <6 kbp, e.g., Figure 2F, lane 11), Cre re-
combinase or the appropriate empty vector control encoding
zeocin resistance (Sh Ble) was introduced into this HTR ‘‘early
passage’’ population (HTREP) (Figures 2A and 2G), and after tran-
sient selection of clonal populations, the excision of hTERT (and
hph) was queried via RT-PCR analysis (Figure 2B, lanes 4–8).
Cell crisis ensued in hTERT-excised populations soon thereafter
(Figure 2C); however, the two longest-lived cell lines supported
anchorage-independent growth immediately after hTERT exci-
sion (Figure 2D, HTREP Cre-3 and HTREP Cre-4). HTREP Cre-4 cells,
although hTERT negative (Figure 2E, lanes 6, 7), formed tumors
in mice at an incidence indistinguishable from hTERT-positive
HTR cells (HTREP Vec) (Figure 2H). This controlled hTERT genetic
excision is consistent with the transient survival observed upon
telomerase suppression in human cancer lines with short telo-
meres (Hahn et al., 1999b; Zhang et al., 1999).(G) Schematic of elements introduced into HA5 cells, at indicated PDL.
Error bars illustrate the standard deviation of the mean, using the number of
replicates as indicated.
Figure 2. Excision of hTERT from Tumor Cells with Short Telomeres
(A) Western analysis of cell lysates (50 mg) in HTREP (early passage) cells transfected with Cre recombinase or empty vector control at indicated population-
doubling level (PDL).
(B) RT-PCR analysis of hTERT, hph, and GAPDH at indicated PDL.
(C) Replicative life span of indicated cell lines. HTREP Vec remained immortal.
(D) Anchorage-independent colony formation at indicated PDL. 293T cells were included as a positive control, and HA5 as a negative control. HTREP Cre-4 at PDL
42 (no colonies) differed significantly from HTREP Cre-4 at PDL 8 (n = 3, *p < 0.05, power(1-b err prob) = 1.0, aactual = 0.05, two tailed).
(E) RT-PCR analysis of hTERT, Sh Ble (zeocin) and GAPDH in tissue extracted from renal capsule (RC) or subcutaneous (SC) injection sites, or normal adjacent
kidney (NK).
(F) TRF analysis of average telomere length at increasing PDL. Weighted mean telomere lengths (kbp) are indicated below each lane.
(G) Schematic of elements introduced into HT cells, at indicated PDL.
(H) Incidence of tumor formation of indicated cell lines in immunodeficient mice (see Experimental Procedures for details).
Error bars illustrate the standard deviation of the mean, using the number of replicates as indicated.TERT-Excised Tumor Cells Exhibit Robust Tumor
Formation until Telomere Crisis
To create hTERT-negative human tumor populations with long
telomeres, the HTR population was propagated in culture for
more than 240 days (PDL 146) until average telomere lengthreached 12 kbp (Figure 3E, lane 11) prior to hTERT excision.
Control cell clones in which an empty vector (HTRVec) was intro-
duced retained hTERT and hph expression, and exhibited telo-
mere elongation and colony forming potential in 0.6% w/v agar
(Figures 3A–3E). In clones selected for Cre recombinaseCell Reports 1, 91–98, February 23, 2012 ª2012 The Authors 93
Figure 3. Excision of hTERT from Tumorigenic Cells with Elongated Telomeres
(A) Telomerase activity in cell lysates (200 ng) from HTRCre and HTRVec clonal cell lines at indicated PDL, controls as specified in Figure 2.
(B) RT-PCR analysis of hTERT, hph, and GAPDH at indicated PDL. HA5 cells were included as a negative control.
(C) Replicative life span of each clonal line, as indicated. HTRVec cells remained immortal.
(D) Anchorage-independent colony growth at increasing PDL, including HA5 and HTR cells as controls (n = 4 each), and 293T cells (n = 3). Difference between the
latest and earliest PDL within each line as indicated (**p < 0.01; ***p < 0.001, power(1-b err prob) = 1.0, aactual = 0.05, two tailed).
(E) TRF analysis of average telomere length at indicated PDL. Weighted mean telomere lengths (kbp) are indicated below each lane.
(F) Analysis of telomere integrity. x axis, individual lines and respective PDL; y axis, average number of telomere signal-free ends (SFE) per metaphase (n = 10).
Brackets indicate a statistically significant difference (p < 0.001, power(1-b err prob) = 1.0, aactual = 0.038-0.044). HTRVec at PDL 169 possessed no SFE.
(G) Relative telomere length of the lines depicted in (F). x axis, telomere fluorescence intensity in arbitrary units; y axis, frequency of events. Early PDL (light gray),
late PDL (dark gray). Graphs are scaled equivalently.
(H) RT-PCR analysis of hTERT,Sh Ble (zeocin resistance) andGAPDH in normal adjacent kidney (NK) or renal capsule (RC). The water control (H20) is the same as
in Figure 2E, lane 11.
Error bars illustrate the standard deviation of the mean, using the number of replicates as indicated.expression (HTRCre), loss of hTERT expression was confirmed by
RT-PCR and measurement of telomerase activity (Figures 3A
and 3B, lanes 1–12). The maximum life span of these hTERT-
excised clones exceeded 250 days, and one clone survived for
1 year (Figure 3C). Telomerase activity remained absent, and
telomere attrition continued unabated with no evidence of the94 Cell Reports 1, 91–98, February 23, 2012 ª2012 The Authorstelomere length heterogeneity typical of telomerase-negative
tumor cells that undergo telomere recombination (ALT) (Figures
3A, 3E, and 3G). Even in the complete absence of hTERT, HTRCre
lines retained a significant initial capacity for anchorage-inde-
pendent growth (Figure 3D). Upon injection into the subrenal
capsule, which in some instances is more permissive for tumor
Figure 4. Ability of hTERT to Rescue Crisis in hTERT-Excised Cells
(A) Wild-type (WT) or mutant (Q169A; D868A, D869A) hTERT or empty vector
(Vec) were introduced into HTREP Cre cells and analyzed for telomerase activity
(200, 100, 50 ng lysate).
(B) Replicative life span of cell lines as indicated above. hTERT WT cells
remained immortal.
(C) Anchorage-independent growth of cell lines as indicated (n = 4).
Statistical significance compared with vector controls as indicated (***p <
0.001, power(1-b err prob) = 1.0, aactual = 0.05, two tailed). Controls and axis
labels as in Figure 2.
Error bars illustrate the standard deviation of the mean, using the number of
replicates as indicated.formation than subcutaneous injection (Liang et al., 2008; Sun
et al., 2005), HTRCre lines exhibited a tumor incidence of 100%
even after more than 1 month in culture (PDL 27) (Figure 2H).
This incidence was indistinguishable from the 100% tumor inci-
dence of telomerase-positive HTRVec cells, and exhibited statis-
tical significance at high probability (a = 0, power = 1.0)
compared with a tumor incidence of zero percent in HTRCre lines
at late passages (PDL 186/189) (Figure 2H). Analysis of HTRCre
tumor explants confirmed the absence of hTERT and retention
of Sh Ble expression specific to HTRCre cells (Figure 3H,
lane 2). The eventual loss of tumor-forming capability and
anchorage-independent growth at later passages was coinci-
dent with the appearance of chromosome ends with no detect-able telomeric DNA (Figures 2H, 3D, 3F, and 3G). These results
demonstrate that longer telomere reserves permit human tumor
formation for prolonged periods in the absence of telomere
maintenance and hTERT, but that the eventual loss of telomeric
DNA leads to crisis and an inability to support tumor formation.
Crisis in TERT-Excised Cells Is Rescued by Catalytically
Active TERT
To confirm that crisis was induced by critically short telomeres
and not via unrelated genetic events, wild-type hTERT or inactive
hTERT mutants Q169A (Sealey et al., 2010; Wyatt et al., 2009) or
D868A/D869A (Harrington et al., 1997) were introduced into
HTREP Cre-4 cells at PDL 6 (Figure 4). Only wild-type hTERT
restored telomerase activity (Figure 4A), extended cellular life
span (Figure 4B), and conferred anchorage-independent growth
(Figure 4C). HA5 cells without HRASG12V also depend on the
catalytic activity of hTERT to avoid crisis (Sealey et al., 2010).
The fact that telomerase catalytic activity was essential to avert
crisis and promote anchorage-independent growth supports the
critical role of hTERT-mediated telomere extension activity in
tumor cell survival when telomeres are short.
DISCUSSION
In the presence of sufficiently long telomeres, telomere erosion
or the absence of hTERT did not impede human tumorigenesis.
Only when telomeric DNA was lost from chromosome ends did
cells resume dependence upon the telomere elongation activity
of hTERT. Other examples of tumor-forming capability in cells
that do not express hTERT are known, for example, in ALT cells
or primary tissues transformed with oncogenic RAS (Liang et al.,
2008; Sun et al., 2005), but these examples did not permit the
ability to test the compatibility of ongoing telomere erosion
with cell survival. Examples of tumors that lack in vitro telome-
rase activity have been correlated with clinical regression (e.g.,
retinoblastoma or neuroblastoma) (Gupta et al., 1996; Hiyama
et al., 1995); however, these studies preceded the cloning of
hTERT or identification of ALT and in many cases these tumor
types are now known to exhibit ALT-like characteristics or low
hTERT expression (reviewed in Cesare and Reddel, 2010).
Here, we showed in a defined genetic system that telomerase-
negative human tumor cells are capable of tumor formation
and cell viability in the absence of endogenous hTERT expres-
sion or ALT.
Although tumorigenic potential has not been examined inmice
lacking Tert, its absence has no phenotypic consequences in
normal murine tissues while telomere reserves remain intact
(Erdmann and Harrington, 2009; Meznikova et al., 2009; Strong
et al., 2011; Vidal-Cardenas and Greider, 2010). The fact that
hTERT is dispensable in telomerase-positive tumor cells was
not foreseen. For example, deletion of one subunit of the Ku
heterodimer, a complex important in maintaining telomere integ-
rity, is lethal in human tumor cells but is dispensable in other
organisms (Fattah et al., 2008; Li et al., 2002). Once telomeres
became critically short, however, aversion of tumor cell crisis
depended upon active TERT. In contrast, when TERT is overex-
pressed, its ability to stimulate proliferation does not always
depend on catalytic activity, e.g., in ALT cells (Stewart et al.,Cell Reports 1, 91–98, February 23, 2012 ª2012 The Authors 95
2002) or murine hair follicles (Flores et al., 2005; reviewed in
Parkinson et al., 2008; Sarin et al., 2005).
Human tumor cells retained their susceptibility to telomere-
induced crisis even after prolonged growth periods. This delayed
dependence upon telomerase function differs from the ‘‘addic-
tion’’ to oncogenic factors such as MYC or RAS, in which cell
survival remains reliant on these factors (Greider, 1999; Wein-
stein and Joe, 2008). Thus, human tumor cells are reliant upon
telomere integrity rather than hTERT or telomerase activity.
Although such dependence was well established for normal
cell growth, it was not possible to predict whether tumor cells
might somehow subvert telomere-induced crisis via induction
of endogenous telomerase, ALT, or another mechanism. For
example, Saccharomyces cerevisiae lacking telomerase and
the recombination factor RAD52 can escape senescence
indefinitely via activation of RAD52-independent telomere main-
tenance mechanisms, provided the strain possesses long telo-
meres initially (Grandin and Charbonneau, 2009; Lebel et al.,
2009). In contrast, our results suggest that human tumor cells
with initially long telomeres can only temporarily avert the
requirement for telomere maintenance.
These results have implications for telomerase inhibition in
cancer therapy. Telomerase-negative pediatric cancers such
as ependymoma possess a better long-term prognosis than
telomerase-positive cancers (reviewed in Tabori and Dome,
2007), and low telomerase expression or ALT correlates with
a better outcome in histiocytoma and colorectal cancer (Matsuo
et al., 2009; Tatsumoto et al., 2000). Our finding that telomerase-
negative tumors do not invoke ALT and remain mortal may
provide a mechanism to explain the more favorable prognosis
for a subset of telomerase-negative tumor types in vivo. Thus,
even in telomerase-positive tumors with long telomeres, telome-
rase inhibition combined with adjunct treatments that limit tumor
progression could prove effective as an anticancer therapy.
EXPERIMENTAL PROCEDURES
Cell Culture
Cell culture and PDL determination was performed as described (Hayflick,
1973; Sealey et al., 2010). hTERT was introduced via electroporation and
clonal populations selected in 200 mg/ml hygromycin (Invitrogen), followed
by retroviral infection with pBABE- puro-HRASG12V (Addgene) (Hahn et al.,
1999a) and selection in 2 mg/ml puromycin (Invitrogen). Transfection with
pcDNA3.1-zeo-Cre (Cre recombinase cDNA provided by Dr. Michael Reth)
or pcDNA3.1-zeo (Invitrogen) was performed using Fugene6 (Roche) with
transient selection in 200 mg/ml zeocin (Invitrogen). Inactive hTERT variants
were introduced as described (Sealey et al., 2010).
Protein and RNA Analysis
Western blots, RT-PCR mRNA analysis, and the telomere repeat amplification
protocol (TRAPeze, Millipore) were performed as described (Sealey et al.,
2010). RT-PCR analysis of mRNA encoding zeocin resistance (Sh Ble) was
conducted using the following DNA primers: 50-GACTTCGTGGAGGACGA
CTT-30 and 50-GACACGACCTCCGACCACT-30. Primary antibodies employed
were anti-SV40 T Ag (Pab-108) (Santa Cruz), anti-HRAS (C-20) (Santa Cruz),
and anti-actin (Sigma).
Anchorage-Independent Growth Assay
Equal cell numbers (53 104) were plated onto 0.6%w/v agar and incubated at
37C (5% v/v CO2) for 21 days as described (Cifone and Fidler, 1980). Colonies
were stainedwith 0.01%w/v crystal violet and images acquiredwith a Bio-Rad96 Cell Reports 1, 91–98, February 23, 2012 ª2012 The AuthorsMolecular Imager Gel Doc XR System. Colonies were counted using Image-
quant TL (GE Healthcare).
Cell Line Injections In Vivo
A suspension of 5 3 105 cells was injected subcutaneously or under the sub-
renal capsule space of Rag2/ / g-chain / immunodeficient mice (Mazurier
et al., 1999). After 21–22 days, the mice were sacrificed and examined.
Explanted tissues were extracted for RNA and analyzed by RT-PCR as
described above. Experiments were performed in accordance with protocols
approved by the Animal Care Committee at the University of Guelph, as out-
lined in the animal utilization protocol AUP08R007 (issued to D.H.B).
Telomere Terminal Restriction Fragment and Q-FISH Analysis
Telomere length was analyzed via terminal restriction fragment (TRF) analysis
(Sealey et al., 2010), and average length determined after Southern blotting
using Imagequant TL and UTSWTELORUN software first developed by
H. Vaziri and C. Harley (Ouellette et al., 2000). Q-FISH was performed as
described (Erdmann and Harrington, 2009) on ten separate metaphases for
each PDL indicated.
Statistical Analysis
Differences in average colony number were assessed via analysis of variance
(ANOVA), assuming unequal variance and using a Tukey post-test (Instat3,
GraphPad). Statistical significance of tumor incidence was assessed using
Fisher’s exact test (Prism5, GraphPad). G*power3 was used to determine
power and alpha values where indicated (Faul et al., 2009). Quantification of
telomere-signal free ends (SFE) after Q-FISH was compared using ANOVA
with a Tukey post-test (Instat3, GraphPad).
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